Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Biocure Technology Inc

Healthcare US BICTF

0.01USD
0.00(0%)

Last update at 2026-06-22T20:00:00Z

Day Range

0.070.07
LowHigh

52 Week Range

0.00140.01
LowHigh

Fundamentals

  • Previous Close 0.01
  • Market Cap0.20M
  • Volume1000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.66756M
  • Revenue TTM-0.00310M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.00106M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -0.10278M -0.26247M -1.49450M -0.40340M -1.47799M
Minority interest - 0.00000M 0.03M 0.06M 0.02M
Net income -0.10278M -0.26247M -1.46714M -0.33844M -0.89171M
Selling general administrative 0.06M 0.31M 0.30M 0.64M 2.34M
Selling and marketing expenses - 0.00925M 0.75M 0.00004M -0.91677M
Gross profit - - - - -
Reconciled depreciation - - - 0.02M 0.08M
Ebit - - -1.46714M -0.67372M -1.50201M
Ebitda -0.09079M - -0.41475M -0.66756M -1.42513M
Depreciation and amortization - 0.32M 1.05M 0.00616M 0.08M
Non operating income net other - - - - -
Operating income -0.09079M -0.31824M -1.05239M -0.67372M -1.42513M
Other operating expenses 0.09M 0.32M 1.49M 0.40M 1.43M
Interest expense 0.01M 0.00001M 0.04M 0.00499M 0.05M
Tax provision - - - - -
Interest income - - - - 0.09M
Net interest income -0.01062M -0.00772M 0.04M -0.00499M -0.40588M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.44211M 0.77M -0.66315M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 0.09M 0.32M 1.49M 0.40M 1.43M
Cost of revenue - - - - -
Total other income expense net -0.01199M 0.06M -0.44211M 0.27M -0.05286M
Discontinued operations - - - - 0.72M
Net income from continuing ops -0.10286M -0.26247M 2.43M -0.40340M -1.14768M
Net income applicable to common shares - - - - -1.12789M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2.01M 1.99M 1.98M 2.08M 4.15M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.00127M - 0.00667M - 1.89M
Total liab 0.43M 0.65M 0.37M 4.41M 5.01M
Total stockholder equity 1.57M 1.34M 1.60M -1.97845M -0.53261M
Deferred long term liab - - - - -
Other current liab 0.38M - - 3.62M -
Common stock 18.00M - 17.68M - 18.38M
Capital stock 18.01M 17.68M 17.68M 18.45M 18.38M
Retained earnings -23.91684M -23.83348M -23.57101M -27.50472M -26.08237M
Other liab - - - - -
Good will - - - - -
Other assets - - - - 0.04M
Cash 0.04M 0.02M 0.00424M 0.04M 0.16M
Cash and equivalents - - - - -
Total current liabilities 0.43M 0.60M 0.33M 4.41M 3.75M
Current deferred revenue - - - - -
Net debt 0.02M 0.03M 0.04M 0.04M 3.63M
Short term debt 0.06M - - - -
Short long term debt 0.06M - - 0.08M 2.53M
Short long term debt total 0.06M - 0.04M - -
Other stockholder equity - - - - 7.17M
Property plant equipment - - - - 0.00769M
Total current assets 0.05M 0.03M 0.01M 0.12M 2.13M
Long term investments 1.97M 1.97M 1.97M 1.97M 1.97M
Net tangible assets - - - - -0.53374M
Short term investments - - - - -
Net receivables 0.00277M - 0.00667M - 0.01M
Long term debt - 0.05M 0.04M - 1.25M
Inventory - - -0.00667M 0.00000M 0.00405M
Accounts payable 0.35M 0.60M 0.33M 0.71M 0.94M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 7.49M - 7.50M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 1.96M 1.97M 1.97M 1.97M 2.02M
Capital lease obligations - - - 0.00000M 0.00364M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00000M 0.08M 0.07M -0.00394M
Change to liabilities - - - - 0.30M
Total cashflows from investing activities - - - - 0.03M
Net borrowings - 0.00000M - - 0.07M
Total cash from financing activities 0.10M 0.00000M 0.14M 0.63M 0.92M
Change to operating activities - - - - -0.04677M
Net income -0.10278M -0.00021M -1.49450M -0.40340M -1.46235M
Change in cash 0.02M 0.00001M -0.03344M -0.11981M 0.11M
Begin period cash flow 0.02M 0.00000M 0.04M 0.16M 0.05M
End period cash flow 0.04M 0.00002M 0.00424M 0.04M 0.16M
Total cash from operating activities -0.07646M 0.00001M -0.21713M -0.81837M -0.85656M
Issuance of capital stock 0.10M 0.00000M - 0.00000M 1.10M
Depreciation - - - 0.02M -0.06078M
Other cashflows from investing activities - - - - 0.45M
Dividends paid - - - - -
Change to inventory - - - 0.00000M 0.00004M
Change to account receivables 0.00504M -0.00114M 0.02M -0.00840M -0.00450M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - 0.19M 0.63M 0.24M
Change to netincome - - - - -0.20445M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00017M 0.00394M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.02M -0.00114M 0.25M 0.50M 0.20M
Stock based compensation - - - 0.00000M 1.16M
Other non cash items 0.01M 0.00136M 0.00769M -0.91641M 0.42M
Free cash flow -0.07646M 0.00001M -0.21713M -0.81837M -0.86049M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BICTF
Biocure Technology Inc		 - -% 0.01 - - 507.55 0.16 554.37 1.87
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Biocure Technology Inc. engages in exploration of mineral properties. The company was founded in 2005 and is headquartered in Vancouver, Canada.

Biocure Technology Inc

1055 West Hastings Street, Vancouver, BC, Canada, V6E 2E9

Key Executives

Name Title Year Born
Dr. Sang Mok Lee Ph.D. Founder, CEO & Director 1966
Dr. Björn Cochlovius Ph.D. Pres NA
Mr. Konstantin Lichtenwald B.B.A., C.P.A., CGA CFO, Corp. Sec. & Director 1984
Mr. Marco Nonni Consultant NA
Dr. Björn Cochlovius Ph.D. President NA
Mr. Konstantin Lichtenwald B.B.A., CPA, CGA CFO, Corporate Secretary & Director 1984
Mr. Yee Sing Cheng CEO & Director 1981

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.